Cargando…
Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees
BACKGROUND: mRNA SARS-CoV-2 vaccines are administered to 2 million individuals per day in the United States under US Food and Drug Administration emergency use authorization. METHODS: Observational cohort study of hospital employees who received their first SARS-CoV-2 mRNA vaccination between 14 Dec...
Autores principales: | Jacobson, Mark A, Zakaria, Adam, Maung, Zaw, Hart, Colin, McCalmont, Timothy H, Fassett, Marlys, Amerson, Erin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244618/ https://www.ncbi.nlm.nih.gov/pubmed/34086881 http://dx.doi.org/10.1093/cid/ciab518 |
Ejemplares similares
-
Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
por: Desai, Amar D, et al.
Publicado: (2022) -
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
por: Straus, Walter, et al.
Publicado: (2022) -
De novo vasculitis after mRNA-1273 (Moderna) vaccination
por: Anderegg, Manuel A., et al.
Publicado: (2021) -
Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022) -
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)